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Antibacterial properties of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile 
Abstract 
The emergence of multidrug-resistant bacterial strains has heightened the need for new antimicrobial 
agents based on novel chemical scaffolds that are able to circumvent current modes of resistance. We 
recently developed a whole-animal drug-screening methodology in pursuit of this goal and now report the 
discovery of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile (PSPC) as a novel antibacterial effective against 
resistant nosocomial pathogens. The minimum inhibitory concentrations (MIC) of PSPC against 
Staphylococcus aureus and Enterococcus faecium were 4 μg/mL and 8 μg/mL, respectively, whereas the 
MICs were higher against the Gram-negative bacteria Klebsiella pneumoniae (64 μg/mL), Acinetobacter 
baumannii (32 μg/mL), Pseudomonas aeruginosa (>64 μg/mL), and Enterobacter spp. (>64 μg/mL). 
However, co-treatment of PSPC with the efflux pump inhibitor phenylalanine arginyl β-naphthylamide 
(PAβN) or with sub-inhibitory concentrations of the lipopeptide antibiotic polymyxin B reduced the MICs 
of PSPC against the Gram-negative strains by >4-fold. A sulfide analog of PSPC (PSPC-1S) showed no 
antibacterial activity, whereas the sulfoxide analog (PSPC-6S) showed identical activity as PSPC across 
all strains, confirming structure-dependent activity for PSPC and suggesting a target-based mechanism of 
action. PSPC displayed dose dependent toxicity to both Caenorhabditis elegans and HEK-293 mammalian 
cells, culminating with a survival rate of 16% (100 μg/mL) and 8.5% (64 μg/mL), respectively, at the 
maximum tested concentration. However, PSPC did not result in hemolysis of erythrocytes, even at a 
concentration of 64 μg/mL. Together these results support PSPC as a new chemotype suitable for further 
development of new antibiotics against Gram-positive and Gram-negative bacteria. 
Disciplines 
Medicine and Health Sciences | Social and Behavioral Sciences 
Publication Details 
Rajamuthiah, R., Jayamani, E., Majed, H., Conery, A. L., Kim, W., Kwon, B., Fuchs, B. Burgwyn., Kelso, M. J., 
Ausubel, F. M. & Mylonakis, E. (2015). Antibacterial properties of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile. 
Bioorganic and Medicinal Chemistry Letters, 25 (22), 5203-5207. 
Authors 
Rajmohan Rajamuthiah, Elamparithi Jayamani, Hiwa Majed, Annie L. Conery, Wooseong Kim, Bumsup 
Kwon, Beth Fuchs, Michael J. Kelso, Frederik M. Ausubel, and Eleftherios Mylonakis 







Antibacterial Properties of 3-(Phenylsulfonyl)-2-
pyrazinecarbonitrile 
Rajmohan Rajamuthiaha,b, Elamparithi Jayamania,b, Hiwa Majedd,e, Annie L. Coneryb, Wooseong 
Kima, Bumsup Kwonc, Beth Burgwyn Fuchsa, Michael J. Kelsod,e, Frederick M. Ausubelb and 
Eleftherios Mylonakisa,b*.  
a Division of Infectious Diseases, Rhode Island Hospital, Alpert Medical School of Brown 
University, Providence, RI 02903, USA. b Massachusetts General Hospital, Harvard Medical 
School, Boston, MA 02114, USA, c Division of Neurology, Rhode Island Hospital, Alpert 
Medical School of Brown University, Providence, RI 02903, USA, d Illawarra Health and 
Medicial Research Institute and e School of Chemistry, University of Wollongong, Wollongong, 
NSW 2522, Australia.  
*Corresponding author:  Eleftherios Mylonakis, Rhode Island Hospital, POB, 3rd floor, 
















The emergence of multidrug-resistant bacterial strains has heightened the need for new 
antimicrobial agents based on novel chemical scaffolds that are able to circumvent current modes 
of resistance. We recently developed a whole-animal drug-screening methodology in pursuit of 
this goal and now report the discovery of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile (PSPC) as a 
novel antibacterial effective against resistant nosocomial pathogens. The minimum inhibitory 
concentrations (MIC) of PSPC against Staphylococcus aureus and Enterococcus faecium were 4 
µg/ml and 8 µg/ml, respectively, whereas the MICs were higher against the Gram-negative 
bacteria Klebsiella pneumoniae (64 µg/ml), Acinetobacter baumannii (32 µg/ml), Pseudomonas 
aeruginosa (>64 µg/ml), and Enterobacter spp. (>64 µg/ml). However, co-treatment of PSPC 
with the efflux pump inhibitor phenylalanine arginyl -naphthylamide (PAN) or with sub-
inhibitory concentrations of the lipopeptide antibiotic polymyxin B reduced the MICs of PSPC 
against the Gram-negative strains by >4-fold. A sulfide analogue of PSPC (PSPC-1S) showed no 
antibacterial activity, whereas the sulfoxide analogue (PSPC-6S) showed identical activity as 
PSPC across all strains, confirming structure-dependent activity for PSPC and suggesting a 
target-based mechanism of action. PSPC displayed dose dependent toxicity to both 
Caenorhabditis elegans and HEK-293 mammalian cells, culminating with a survival rate of 16% 
(100 µg/mL) and 8.5% (64 µg/mL), respectively, at the maximum tested concentration. 
However, PSPC did not result in hemolysis of erythrocytes, even at a concentration of 64 µg/mL. 
Together these results support PSPC as a new chemotype suitable for further development of 
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Antibiotic resistance is a looming health crisis as pathogens gain increased resistance to 
our current arsenal of clinically useful drugs.1 The “golden age” of antibiotic drug discovery in 
the previous century revolutionized health care and together with vaccination contributed to the 
steep decline in infectious disease associated mortality, especially in developed countries.2 Since 
then, further developments in treatment options have mostly relied on incremental improvements 
of existing structural classes of drugs.3 Meanwhile, rampant overuse of antibiotics in both 
humans and agriculture has resulted in bacterial populations that are resistant to even the most 
powerful drugs available, many of which were meant to be used as last resort drugs partly due to 
their superior activity and their toxic side effects.4 Therefore, it is apparent that new structural 
classes of drugs and new treatment strategies are urgently needed.  
 We previously reported the development of a Caenorhabditis elegans-based whole 
animal infection model for simultaneous high throughput in vivo screening for compounds that 
are both efficacious against methicillin resistant S. aureus (MRSA) and which exhibit low levels 
of eukaryotic toxicity.5 In the current study, we used a C. elegans-MRSA assay to screen 21,472 
small molecules supplied by Boehringer Ingelheim GmbH (BI) and identified several hits that 
prolonged the survival of infected worms. In this study we have characterized the antimicrobial 
properties of the novel compound 3-(phenylsulfonyl)-2-pyrazinecarbonitrile (PSPC). PSPC 
displays strong antimicrobial activity against Gram-positive bacteria and is also effective against 
Gram-negative bacteria, especially in combination with an efflux pump inhibitor or lipopeptide 
antibiotic. In vivo infection studies in C. elegans showed that PSPC is comparable to vancomycin 
in prolonging survival of MRSA infected worms at a concentration as low as 0.78 µg/mL, 
though it is also toxic to nematodes at high concentrations. PSPC does not cause hemolysis of 





concentration of 4 µg/mL. These findings support the need for further studies to improve the 
antibacterial potency and diminish the toxicity of PSPC before in vivo testing in mammalian 
infection models.   
 
Identification of PSPC as a hit compound that prolongs survival of C. elegans infected with 
MRSA 
The C. elegans-MRSA liquid infection assay is a well-established high throughput 
screening platform that allows simultaneous assessment of both the toxicity and antibacterial 
efficacy of test compounds in 384-well formats.5-7 The end point of the assay is to measure the 
survival of MRSA-infected worms that have been treated with test compounds. This liquid 
infection assay was used to identify antibacterial hits from a library of 21,472 pre-selected 
compounds provided by Boehringer-Ingelheim GmbH (BI). The compounds were pin-transferred 
to 384-well plates at a final assay concentration of 20 µg/mL. Each sample plate contained 16 
wells each of positive control (vancomycin at 10 µg/mL in 1% DMSO) and negative control (1% 
DMSO). The percent survival of infected worms treated with library compounds was determined 
at the end of the assay and a Z score was calculated for each well to identify hits. Of the 21,472 
compounds tested, 318 (1.4% hit rate) protected worms from MRSA-mediated death. Among the 
hits, PSPC (Fig. 1) was chosen for follow up studies because the compound is a novel, low 






Figure 1. Chemical structures of 3-(Phenylsulfonyl)-2-pyrazinecarbonitrile (PSPC) and its 
sulfide (PSPC-1S) and sulfoxide (PSPC-6S) analogues. 
 
To confirm the activity of PSPC, the compound was resynthesized (see Supporting 
Information) and the C. elegans-MRSA liquid infection assay was repeated using serial dilutions 
in the range of 0.78-100 µg/mL. The activity of the resynthesized PSPC was compared to 
vancomycin over the same concentration range. At the lowest concentration, both PSPC and 
vancomycin were effective in prolonging survival of more than 90% of infected worms (Fig. 2). 
However, at the higher concentrations of 50 and 100 µg/mL, worms treated with PSPC showed 
only 46% and 16% survival, respectively, whereas vancomycin-treated worms showed >97% 
survival at these concentrations. These findings suggest that although PSPC ameliorates MRSA-
associated lethality in worms at low concentration, the compound is toxic to the worms at higher 
concentrations. The concentration of DMSO in all sample wells did not exceed 1% DMSO, the 
concentration of DMSO in the negative control, and therefore, the toxicity of PSPC at higher 






Figure 2. PSPC prolongs survival of C. elegans infected with S. aureus (MRSA). 
(A) 384-well assay plate was co-inoculated with young adult stage C. elegans glp-4(bn2);sek-
1(km4) animals, MRSA strain MW2, and either DMSO (negative control), or 2-fold serial 
dilutions (0.78-100 μg/mL) of vancomycin (positive control) or PSPC. (A) Sytox Orange-stained 
and brightfield images of assay wells containing serial dilutions of the drugs. Dead worms take 
up the vital dye Sytox Orange and fluoresce.  
(B) Percent survival of infected worms was calculated from the ratio of fluorescent worm areas 






In vitro antibacterial activity of PSPC  
As we have previously described, compounds identified in chemical screens that prevent 
a pathogen from killing C. elegans, can inhibit the growth of the pathogen, block the virulence of 
the pathogen, and/or enhance C. elegans immunity.8-10 To help distinguish these possibilities, we 
determined first whether PSPC could directly affect the growth of the pathogen.  We found that 
PSPC does inhibit the growth of the MRSA strain MW2 in Müller-Hinton broth with an in vitro 
MIC of 4 µg/ml, compared to an MIC of 2 µg/ml for vancomycin (Table 1). A time-kill assay at 
10x MIC (40µg/ml) showed that PSCP is bactericidal, killing essentially 100% of MW2 cells 
during a 4-hour exposure period (Fig. 3).  The minimum bactericidal concentration of PSPC 
against MW2 is 16 µg/ml (data not shown), 4 times the MIC.  These data show that PSPC 
functions directly to block the growth of MRSA MW2.   
 
Figure 3. Time-kill kinetics of PSPC against S. aureus. 



















E. faecium (E007) 4 ND 8 >64 8 
S. aureus (MW2) 2 ND 4 >64 4 
K. pneumoniae 
(77326) 
ND 16 64 >64 64 
A. baumannii 
(ATCC 17978) 
ND 0.5 32 >64 32 
P. aeruginosa 
(PA14) 
ND 2 >64 >64 >64 
Enterobacter spp. 
(KCTC 2625) 
ND 32 >64 >64 >64 
 
 
The ability of PSPC to function as a broad-spectrum antibiotic was determined by 
measuring its MIC against the ESKAPE pathogens: E. faecium, K. pneumoniae, A. baumannii, P. 
aeruginosa and Enterobacter spp, in addition to S. aureus. The six ESKAPE pathogens are the 
main causes of nosocomial infections, which are often difficult to treat due to antimicrobial 
resistance.11 Similar to S. aureus, the MIC of PSPC against the Gram-positive species E. faecium 
was 8 µg/mL (Table 1), but PSPC displayed higher MICs against the Gram-negative bacteria K. 
pneumoniae (64 µg/mL), A. baumannii (32 µg/mL), P. aeruginosa (>64 µg/mL) and 
Enterobacter spp. (>64 µg/mL).  
 
A PSPC analogue has antimicrobial activity 
Two analogues of PSPC were synthesized (see Supplementary Methods) and tested for 
antibacterial activity against the ESKAPE pathogens (Table 1). The sulfide analogue PSPC-1S 





the sulfoxide analogue PSPC-6S (Fig. 1) showed identical potency to PSPC against all species. 
These findings indicate that the activity of PSPC is structure-dependent and requires the polar 
functionality attached to the sulfur atom, which supports a target-based mechanism. 
 
The efflux pump inhibitor PAβN potentiates the activity of PSPC against Gram-negative 
bacteria 
The peptidomimetic compound phenylalanine arginyl -naphthylamide (PAN) is a 
broad spectrum pump inhibitor that is effective against resistance/nodulation/division (RND) 
pumps in various Gram-negative bacteria, restoring the antibiotic susceptibility of these strains.12 
We examined whether PAN also possessed the ability to directly inhibit the growth of bacteria, 
by testing the antimicrobial activity of PAN against the Gram-negative ESKAPE pathogens in a 
broth microdilution assay. PAN did not show any growth inhibitory effects against these strains 
at the maximum tested concentration of 64 µg/mL (data not shown). Accordingly, we examined 
whether the activity of PSPC against Gram-negative ESKAPE pathogens could be potentiated in 
the presence of PAN at a fixed concentration of 64 µg/mL. In the presence of PAN, the MIC 
of PSPC against K. pneumoniae, A. baumannii, P. aeruginosa and Enterobacter spp. decreased 


















PSPC +  
PAN (64 
µg/mL) 
K. pneumoniae (ATCC 77326)  64 8 8 
A. baumannii (ATCC 17978)  32 4 8 
P. aeruginosa (PA14)  >64 16 >4 
Enterobacter spp. (KCTC 2625) >64 8 >8 
 
 
PSPC acts synergistically with polymyxin B against K. pneumoniae and A. baumannii 
 We tested the ability of polymyxin B, a lipopeptide antibiotic that is effective against a 
variety of Gram-negative bacteria, to function synergistically with PSPC against K. pneumoniae 
and A. baumannii. A microplate checkerboard assay was used to test for growth inhibition of the 
strains in the presence of PSPC adjusted to final concentrations in the range of 1-64 μg/mL and 
polymyxin B adjusted to final concentrations of 0.063-64 μg/mL. The minimum concentrations 
at which the two compounds inhibited bacterial growth, both alone and in combination, were 
determined in order to calculate the Fractional Inhibitory Concentration (FIC) index.13 The FIC 
indices of polymyxin B/PSPC against K. pneumoniae and A. baumannii were found to be 0.141 
and 0.375, respectively (Table 3). FIC indices <0.5 indicate that polymyxin B exhibits 












PSPC Polymyxin B 




64 16 1 and 2 0.141 
A. baumannii 
(ATCC 17978) 
32 0.5 4 and 0.125 0.375 
 
 
Cytotoxicity and hemolytic activity of PSPC 
  PSPC was found to be toxic to worms at high concentrations (Fig. 2), suggesting the 
possibility of toxicity to other eukaryotic systems. In vitro cytotoxicity of PSPC was evaluated 
against HEK-293 cells. The cells were treated with serial dilutions of PSPC over the 
concentration range 1-64 μg/mL and cell viability determined. The mitochondrial toxin rotenone, 
which interferes with the electron transport chain in mitochondria, was included as a positive 
control. At concentrations up to 2 μg/mL of PSPC, almost 90% of treated cells survived (Fig. 
4A). Higher concentrations of PSPC caused a dose dependent increase in toxicity to HEK-293 
cells, culminating in a survival rate of only 8.5% at 64 μg/mL, which is the maximum 
concentration tested (Fig. 4A).  
We also tested whether PSPC could have lytic activity that would contribute to the 
toxicity by measuring the hemolysis of sheep erythrocytes.  Sheep red blood cells (RBCs) were 





dilutions of Triton X-100 (0.001-1%) were used as a positive control. PSPC did not cause visible 
RBC hemolysis at the maximum concentration tested (Fig. 4B), which was confirmed by 
measuring absorbance at 540 nm (data not shown). Triton X-100 caused hemolysis at all 
concentrations above 0.008%. The findings suggest that PSPC does not cause damage to 






Figure 4. Cytotoxicity and hemolytic activity of PSPC. 
(A) The viability of HEK-293 cells was measured after treatment with serially diluted 
concentrations (1-64 μg/ml) of PSPC or the mitochondrial toxin rotenone (positive control). Cell 
viability was measured spectrophotometrically by detecting degradation of WST-1 dye into 
formazan by viable cells, which produces measurable color. 
(B) Sheep erythrocytes were treated with serial dilutions of Triton X-100 (.001-1%) or PSPC 
(0.063-64 μg/ml). 
 
Using a C. elegans – MRSA whole animal high throughput screening assay, we identified 
a novel antibiotic, PSPC, and its analogue, PSPC-1S, that are effective against the Gram positive 
bacteria S. aureus and E. faecium at MICs of 4 and 8 µg/ml, respectively.   In earlier studies, we 
described the use of C. elegans infection assays to identify “immunomodulators” in addition to 
traditional antibiotics that directly inhibit bacterial growth.8, 10, 14 As the name suggests, immune-
modulators do not display direct effects on the pathogen, but rather act by modulating the 
immune system of the host to fight the infection. Although our findings show that PSPC displays 
direct antibacterial activity against Gram-positive bacteria and to a lesser extent against Gram-
negatives, interestingly, the minimum effective concentration (MEC) of PSPC in vivo was ≤ 0.78 
µg/mL, which is ≥5-fold lower than its in vitro MIC against S. aureus.  This suggests that PSPC 
might have immunomodulatory properties in addition to its antibacterial effects, similarly to 
another compound that we have studied, RPW-24, that was identified in a screen for anti-
infective compounds against Enterococcus faecalis using a C. elegans liquid infection assay 15.   
The anti-infective properties of RPW-24 in C. elegans were attributed to the ability of the 
compound to promote the expression of endogenous immune effector molecules via 





vancomycin was also several fold lower than the MIC, suggesting that the enhanced in vivo 
activity of PSPC could also be due to bioaccumulation of the molecule in the infected worms.  
Another possibility for why the MEC in vivo is lower than the MIC in vitro is that the C. elegans 
immune system (i.e. by modulating the production of antimicrobial peptides) sensitizes certain 
pathogens to particular classes of antibiotics. 
Reasons for the differential activity of PSPC and PSPC-6S against Gram-positive and 
Gram-negative bacteria could be due to the structural and molecular differences between the two 
classes of bacteria. Alternatively, the action of efflux pumps in transporting PSPC and PSPC-6S 
out of Gram-negative bacteria may contribute to the higher MICs. Efflux pumps have been 
implicated in resistance of P. aeruginosa to tetracycline, chloramphenicol and norfloxacin 16-17, 
agents that remain effective against Gram-positive bacteria, including S. aureus. Among the 
several categories of efflux pump systems in Gram-negative bacteria, the RND system is 
constitutively active and plays a major role in resistance to many antibiotics, including β-lactams, 
fluoroquinolones, and aminoglycosides.18 It is likely that PAN potentiated the activity of PSPC 
against Gram-negative bacteria, through inhibition of efflux pumps. Interestingly, a recent study 
has shown that PAN was also capable of permeabilizing bacterial membranes, at a 
concentration of 50 µg/mL, which can increase uptake of small molecules into bacteria from the 
surrounding environment.19 Therefore, there could be several ways by which PAN potentiates 
the activity of PSPC, including efflux pump inhibition and possibly also by enhancing uptake of 
PSPC by the bacterial cell. Further studies are therefore needed to confirm the mechanism by 
which PAN potentiates the action of PSPC against Gram-negatives.  
We also found that polymyxin B synergistically potentiates the activity of PSPC against 





range of Gram-negative bacteria, but was rarely used clinically until recently due to its 
nephrotoxicity and neurotoxicity.20 The rationale for testing polymyxin B in combination with 
PSPC was that if they functioned synergistically, relatively low concentrations of each drug 
could be used, reducing their toxicity. The mode of action of polymyxin B involves binding to 
bacterial outer membranes, causing disruptions that lead to rapid cell death.21 The drug has re-
entered clinical practice in recent times due to the emergence of multidrug-resistant nosocomial 
Gram-negative infections and the dwindling antibiotic development pipeline.21 Resistance to 
polymyxin B is infrequent, although it has been increasing in recent years.22 The primary 
mechanism of resistance involves modifications to the bacterial outer membrane that reduces 
membrane affinity for the drug.21  
In conclusion, we report the identification of PSPC as a hit anti-bacterial from a high 
throughput screen involving a C. elegans-MRSA liquid infection assay. Antimicrobial 
susceptibility profiling suggests that PSPC shows moderate activity against the Gram-positive 
ESKAPE pathogens and exhibits synergism with polymyxin B against the Gram-negative 
ESKAPE species. The activity of PSPC against Gram-negative bacteria was enhanced by co-
treatment with the efflux pump inhibitor PAN. Although the mechanism of action of PSPC still 
needs to be resolved, total loss of activity with a simple sulfide analogue of PSPC (i.e. PSPC-1C) 
supports the hypothesis that the compound may act via a target-based mechanism. Further tests 
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